What medications can relax the bladder and improve voiding in a woman with detrusor overactivity or a relatively tight bladder outlet?

Medications to Relax the Bladder and Ease Voiding in Women

For women with detrusor overactivity causing urgency and frequency, start with bladder training first, then add antimuscarinic medications (oxybutynin, tolterodine, darifenacin, solifenacin, fesoterodine, or trospium) or the beta-3 agonist mirabegron if behavioral therapy fails; however, for women with incomplete bladder emptying due to a tight bladder outlet, alpha-adrenergic antagonists may facilitate voiding by relaxing the bladder neck and proximal urethra, though you should avoid antimuscarinics entirely in this scenario as they will worsen retention. 1, 2

Critical Distinction: Overactive vs. Underactive Bladder

The medication approach depends entirely on whether the problem is storage (overactive bladder) or emptying (underactive bladder/retention):

For Detrusor Overactivity (Storage Problem)

First-line non-pharmacologic therapy:

• Begin with bladder training for urgency symptoms, which involves scheduled voiding every 2-3 hours and gradually increasing intervals 1
• Add pelvic floor muscle training with bladder training for mixed incontinence 1
• These behavioral interventions are effective, have minimal adverse effects, and are less expensive than medications 1

Pharmacologic therapy (second-line):

• Antimuscarinic agents are the primary medications for detrusor overactivity, working by blocking acetylcholine at muscarinic receptors to reduce involuntary detrusor contractions 1, 3, 4
• Available antimuscarinics include: oxybutynin, tolterodine, darifenacin, solifenacin, fesoterodine, and trospium—all are equally efficacious 1, 5
• Choose based on tolerability and side effect profile rather than efficacy, since all work similarly well 1
• Tolterodine causes fewer adverse effects than oxybutynin, while solifenacin has the lowest discontinuation rate due to side effects 1
• Common side effects include dry mouth, constipation, and blurred vision 1

Beta-3 adrenergic receptor agonist:

• Mirabegron is an alternative that works by inhibiting afferent nerve signals and preventing acetylcholine release 6, 7
• Side effects include hypertension, nasopharyngitis, and urinary tract infections 6
• Particularly useful when antimuscarinics are not tolerated 6, 7

For Incomplete Bladder Emptying (Voiding Problem)

Critical warning: If the woman has incomplete emptying with elevated post-void residual (>100 mL), do not use antimuscarinic medications—they will impair detrusor contractility and worsen retention 2, 8

Pharmacologic options for facilitating emptying:

• Alpha-adrenergic antagonists (α-blockers) relax smooth muscle at the bladder neck and proximal urethra, decreasing outlet resistance and facilitating bladder emptying 2, 9, 3, 8
• These work by antagonizing α-1 adrenergic receptors concentrated at the bladder neck and urethra 2
• Evidence is limited and based on small, non-randomized studies 2

Ineffective medications to avoid:

• Cholinergic agonists (bethanechol) have not been demonstrated to be effective for treating underactive detrusor function despite theoretical rationale 1, 2, 3

Common Pitfalls and How to Avoid Them

Pitfall #1: Using antimuscarinics in women with retention

• Always measure post-void residual before starting antimuscarinic therapy 2
• If PVR >100 mL, antimuscarinics are contraindicated as they will worsen incomplete emptying 2, 6

Pitfall #2: Starting medications before behavioral therapy

• Up to 20% of cases improve with conservative measures alone 1
• Always trial bladder training for 4-8 weeks before adding pharmacotherapy 9

Pitfall #3: Ignoring concurrent constipation

• 66% of patients with incomplete emptying improve after treating constipation alone 2
• Address bowel dysfunction concurrently, as it significantly impairs bladder function 1, 2

Pitfall #4: Not monitoring blood pressure on mirabegron

• Mirabegron can increase blood pressure or worsen existing hypertension 6
• Check blood pressure regularly during treatment 6

Monitoring Treatment Response

• Reassess symptoms at 1-2 months after starting medication, then every 3-6 months 9
• Use voiding diaries to track frequency, urgency episodes, and incontinence 1, 2
• For women with retention on α-blockers, repeat uroflowmetry and post-void residual measurements regularly 2, 9
• Many patients discontinue antimuscarinic therapy due to adverse effects, so proactively discuss tolerability 1

When Medications Are Not Appropriate

Stress urinary incontinence:

• Do not use systemic pharmacologic therapy for pure stress incontinence—it is not effective 1
• Vaginal estrogen formulations may improve stress incontinence in postmenopausal women, but transdermal estrogen worsens it 1